Ensign Peak Advisors, Inc Kronos Bio, Inc. Transaction History

Ensign Peak Advisors, Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.34 - $2.62 $436,375 - $853,210	-325,653 Reduced 95.28%	16,150 $23,000
Q4 2022 Feb 13, 2023	SELL	$1.44 - $3.44 $90,967 - $217,311	-63,172 Reduced 15.6%	341,803 $553,000
Q2 2022 Aug 12, 2022	SELL	$3.12 - $7.52 $111,427 - $268,569	-35,714 Reduced 8.1%	404,975 $1.47 Million
Q1 2022 May 16, 2022	SELL	$6.26 - $14.42 $121,832 - $280,642	-19,462 Reduced 4.23%	440,689 $3.19 Million
Q4 2021 Feb 11, 2022	BUY	$11.35 - $21.18 $146,823 - $273,984	12,936 Added 2.89%	460,151 $6.25 Million
Q3 2021 Nov 12, 2021	SELL	$18.17 - $24.7 $616,944 - $838,663	-33,954 Reduced 7.06%	447,215 $9.37 Million
Q2 2021 Aug 13, 2021	BUY	$20.08 - $29.02 $602,400 - $870,600	30,000 Added 6.65%	481,169 $11.5 Million
Q1 2021 May 12, 2021	BUY	$27.0 - $32.48 $6.41 Million - $7.71 Million	237,278 Added 110.93%	451,169 $13.2 Million
Q4 2020 Feb 12, 2021	BUY	$26.68 - $38.23 $5.71 Million - $8.18 Million	213,891 New	213,891 $6.39 Million

19.8M

9.3K

100

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $53.9M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.